BYDUREON Drug Patent Profile

Which patents cover Bydureon, and when can generic versions of Bydureon launch?

Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the exenatide synthetic profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bydureon

A generic version of BYDUREON was approved as exenatide synthetic by AMNEAL on November 19^th, 2024.

Summary for BYDUREON

International Patents:	307
US Patents:	6
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BYDUREON

US Patents and Regulatory Information for BYDUREON

BYDUREON is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		DISCN	Yes	No					Y
Astrazeneca Ab	BYDUREON BCISE	exenatide synthetic	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		DISCN	Yes	No					Y

International Patents for BYDUREON

When does loss-of-exclusivity occur for BYDUREON?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Chile

Denmark

European Patent Office

Japan

Mexico

Serbia

Slovenia

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BYDUREON around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	026024	COMPUESTOS INHIBIDORES SGLT2 DE GLUCOSIDOS DE C-ARILO Y METODO, LAS COMPOSICIONES FARAMCEUTICAS QUE LOS CONTIENEN Y LOS INTERMEDIARIOS DE SINTESIS DEDICHOS COMPUESTOS
Argentina	040032	C-ARIL-GLUCOSIDOS COMO INHIBIDORES DE SGLT2 Y METODO
Austria	295848
Austria	353334
Australia	2003237886	C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD

Supplementary Protection Certificates for BYDUREON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1734971	C01734971/01	Switzerland		PRODUCT NAME: EXENATIDE; REGISTRATION NO/DATE: SWISSMEDIC 61629 17.02.2012
1140145	SZ 30/2007	Austria		PRODUCT NAME: EXENATIDE
1734971	PA2012006	Lithuania		PRODUCT NAME: EXENATIDUM; REGISTRATION NO/DATE: EU/1/11/696/001 - EU/1/11/696/002 20110617
1506211	122014000070	Germany		PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, WIE DURCH DAS GRUNDPATENT GESCHUETZT; REGISTRATION NO/DATE: EU/1/13/900 20140116
1734971	C20120006 00104	Estonia		PRODUCT NAME: EKSENATIID;REG NO/DATE: K(2011)4479 LOPLIK 23.06.2011

Last updated: July 6, 2026

BYDUREON (exenatide ER) investment scenario and patent/IP fundamentals analysis

Executive summary: BYDUREON’s US commercial path is largely defined by (1) the Orange Book patent estate tied to exenatide extended-release (ER) and its delivery system, (2) the near-term availability of GLP-1 products replacing exenatide ER in prescriber and payer decisions, and (3) the fact that BYDUREON has been discontinued in multiple markets. From an investor perspective, the risk-adjusted outlook is constrained by older IP, competitive therapeutic displacement, and limited upside from new entrants unless there are remaining enforceable patents for specific dosage forms or manufacturing methods.

---

What patents protect BYDUREON (exenatide ER) in the US, and how many are still enforceable?

Featured snippet answer: BYDUREON’s protectable core is exenatide extended-release composition and the delivery/micro-sphere or depot formulation, with additional coverage for manufacturing methods and/or specific use claims depending on the filing family. The enforceability window is tied to Orange Book-listed patents for the approved NDA.

Patent estate mapping approach for BYDUREON A BYDUREON-focused IP scan should be built around four buckets that repeatedly drive litigation and generic viability in the GLP-1 ER class:

1. Formulation patents (composition of matter or formulation)
   • Exenatide ER particle/depot composition, stabilizers, polymer matrix, and drug release-control components.
2. Delivery device / kit patents
   • Reconstitution systems, needle assemblies, and the delivery mechanics of the ER suspension kit (where claimed).
3. Manufacturing process patents
   • Critical steps such as particle formation, sterilization, aseptic filling, lyophilization or suspension manufacturing controls (as claimed).
4. Method-of-use patents
   • Claiming glycemic outcomes in specific patient subsets, dosing regimens, or combinations.

Practical implication for investors

• If the remaining enforceable patents are predominantly formulation or process claims, generic makers typically require either design-around or a Paragraph IV posture with heavy litigation burn.
• If remaining claims are narrow and formulation-specific, commercial risk shifts to product readiness timing and ability to clear regulatory comparability.

Data gap constraint No Orange Book patent numbers, expiration dates, or claim scopes are provided in the prompt, and a complete, accurate estate cannot be produced without that dataset.

---

When does BYDUREON lose exclusivity in the US, and what drives the last generic-blocking date?

Featured snippet answer: Exclusivity loss for BYDUREON is governed by the later of (1) expiration of Orange Book-listed patents and (2) any pediatric exclusivity or other statutory exclusivity attached to the NDA, if applicable.

Key drivers investors track

• Patent expiration vs. exclusivity expiration: These are different events. Patent term is time-based; exclusivity is NDA-specific and can include pediatric exclusivity.
• NDA lifecycle events: Switches in formulation, changes in manufacturing site, or supplemental approvals can add listings or create new patent families.
• Litigation stay and settlement dynamics: A Paragraph IV filing can lead to a 30-month stay of approval, and settlements can shift launch timing even if patents expire during litigation.

Data gap constraint A precise exclusivity and last-blocking date requires Orange Book listing and exclusivity identifiers.

---

What is the Orange Book status of BYDUREON (exenatide ER), and which patents are listed for which strengths/dosage forms?

Featured snippet answer: BYDUREON’s Orange Book entries enumerate specific patent numbers mapped to the approved NDA and labeled strengths/formulations. Those entries drive FDA eligibility for ANDA/505(b)(2) pathways and patent challenge strategy.

What an investable Orange Book table should include For each strength/dosage form (and any kit variant), investors typically build a matrix:

NDA	Strength	Patent #	Patent type	Expiration	Status (active/expired)	Notes (formulation/process/use)
BYDUREON NDA	e.g., X mg	######	Composition/process	YYYY-MM-DD	Active	Depot formulation / particle size control

Data gap constraint No Orange Book listing content is included in the prompt, so a precise status table cannot be generated.

---

How strong is the patent estate for BYDUREON exenatide ER formulation and manufacturing methods?

Featured snippet answer: BYDUREON’s IP strength typically concentrates in ER depot/formulation and manufacturing process claims. The enforceability strength depends on claim breadth and whether courts have previously limited similar exenatide ER patents.

Investor lens on “strength” Investors should separate three strength dimensions:

1. Breadth
   • Claim language that covers a wide range of particle morphologies, polymers, release kinetics, and manufacturing tolerances.
2. Evidence of commercial dependence
   • Whether the commercial product’s performance depends on the patented aspects.
3. Litigation track record
   • Whether the patent family survives invalidity and design-around attempts.

Data gap constraint Specific strength requires cited patent numbers, prosecution history indicators, and any litigation outcomes for the relevant families.

---

What patent litigation affects BYDUREON (exenatide ER), including Paragraph IV challenges and settlements?

Featured snippet answer: Paragraph IV challenges usually hinge on noninfringement and/or invalidity arguments targeting formulation/process claims. Settlements commonly convert patent dispute outcomes into a deferred generic launch date.

Investor checklist for litigation-linked value

• Identify each Paragraph IV ANDA associated with the BYDUREON NDA.
• Record:
  • notice dates
  • whether a 30-month stay was triggered
  • settlement date and launch trigger
  • court rulings (infringement/invalidity)
  • final FDA approval date post-litigation

Data gap constraint No litigation docket identifiers or settlement dates are present in the prompt.

---

What generic entry risks exist for BYDUREON, and which product design-arounds are most likely?

Featured snippet answer: Generic entry risk is highest where patents are narrow to specific depot compositions or specific manufacturing steps, enabling alternative-release profiles or alternate particle matrices that still meet FDA equivalence.

Most common design-around levers in ER injectables

• Swap polymer matrix compositions while preserving exenatide release profiles.
• Modify particle size distribution or dispersion chemistry to avoid formulation claim elements.
• Alter manufacturing steps that are claim-critical (e.g., particle formation sequence).
• Pursue alternate kit configurations if delivery system is not broadly claimed.

Investment implication

• If remaining enforceable claims cover core release-control composition broadly, generic entry is delayed and less likely to be commercially viable.
• If claims are narrow and design-arounds succeed, investor risk increases because generic market entry compresses pricing.

Data gap constraint A valid risk assessment needs the remaining claim scope and litigation outcomes.

---

How does BYDUREON compare with other GLP-1 therapies (Ozempic, Trulicity, Rybelsus) for investment upside and downside?

Featured snippet answer: BYDUREON competes in the GLP-1 market where once-weekly and daily oral/semi-oral options have shifted prescribing toward newer agents with better adherence profiles, payer contracts, and broader clinical differentiation.

Competitive displacement dynamics that matter to investors

• Payer preference: Tier placement and formulary coverage increasingly favor newer GLP-1 options.
• Patient preference: Injection frequency, tolerability, and training burden affect persistence.
• Clinical positioning: If newer agents achieve superior HbA1c and weight outcomes across subgroups, exenatide ER demand can erode faster.

Data gap constraint The prompt does not provide BYDUREON sales, market share, or discontinuation timelines by geography, which limits a quantitative comparison.

---

What is the FDA regulatory pathway landscape for BYDUREON generics or reformulations (ANDA vs 505(b)(2))?

Featured snippet answer: A generic route (ANDAs) typically targets an established NDA reference listed drug and must meet bioequivalence and satisfy patent certification requirements. Reformulation or new delivery approaches can move through 505(b)(2), potentially reusing literature/bridging studies.

Investor considerations

• 505(b)(2) can reduce reliance on a single reference product but may still be blocked by listed patents.
• Competitive entry depends on:
  • bioequivalence feasibility for ER suspension/depot
  • ability to scale manufacturing reproducibly
  • compatibility with labeling and interchangeability policies

Data gap constraint No NDA references, listed drug identifiers, or regulatory milestones are provided.

---

What dose/strength changes or formulation variants exist for BYDUREON, and do they create separate patent pockets?

Featured snippet answer: Supplemental approvals for strength changes, kit revisions, or formulation manufacturing changes can add patent listings and create separate IP pockets even within the same NDA.

Why this matters commercially

• A “same active, same therapeutic class” product can face different IP protection if:
  • the depot formulation differs
  • release kinetics are adjusted
  • kit reconstitution or device elements change (if claimed)

Data gap constraint No strength variants or patent listings per variant are provided.

---

Which companies are positioned to challenge BYDUREON, and what does that imply for investment timing?

Featured snippet answer: Generic and biosimilar competitors signal timing risk when they file ANDAs with Paragraph IV certifications and pursue litigation or settlement.

Investor implication

• A high-confidence challenge cluster compresses the effective remaining patent value and increases downside from price erosion.
• Sparse or inactive challenge activity can support longer commercial monetization, but product discontinuation and class displacement can still dominate.

Data gap constraint No challenger names, ANDA numbers, or certification records are present in the prompt.

---

Investment scenario: Bull, base, and bear cases for BYDUREON based on IP and competitive substitution

Featured snippet answer: The core bull case requires sustained enforceable patent coverage plus continued payer access and low disruption from generic entry. The bear case is driven by displacement from newer GLP-1 agents plus generic entry and/or product discontinuation.

Bull case drivers

• Remaining enforceable Orange Book patents block ANDA entry.
• Limited Paragraph IV activity and unfavorable litigation outcomes for challengers.
• BYDUREON maintains formulary presence in at least some payer segments.

Base case drivers

• Patent clock reduces effective protection over time.
• Competition from other GLP-1s compresses growth, but BYDUREON retains a residual niche.
• Generic pressure emerges late but without immediate total collapse.

Bear case drivers

• Earlier-than-expected generic entry or design-around succeeds.
• Sustained formulary down-tiering or discontinuations reduce addressable market.
• Any remaining IP is narrow and easily bypassed.

Data gap constraint No sales or patent timeline inputs are provided, so this is structured scenario logic rather than quantified valuation.

---

Key Takeaways

• BYDUREON’s investment fundamentals hinge on the remaining enforceable Orange Book patent estate for exenatide ER depot formulation and manufacturing, plus the state of generic litigation and settlements.
• Competitive substitution across the GLP-1 class increases demand risk regardless of IP, especially where newer agents dominate payer and prescriber preference.
• Without Orange Book listing content (patent numbers and expirations) and litigation records (Paragraph IV filings, outcomes, settlements), a complete, decision-grade patent/IP clock for BYDUREON cannot be produced from the provided prompt.

---

FAQs

1. How do formulation patents for exenatide ER typically block generic ANDAs for long-acting injectables?
2. What happens to generic launch timing if BYDUREON patent litigation settles during the 30-month stay period?
3. Does a kit or reconstitution change for BYDUREON create separate FDA-listed patents by dosage form?
4. How do ER bioequivalence requirements differ from immediate-release GLP-1 products for ANDA feasibility?
5. What KPIs best indicate BYDUREON demand displacement by newer GLP-1 therapies in US payer formularies?

---

References

No sources were provided in the prompt; no claims are backed by cited documents.